Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLUTION trial of evolocumab before PCI in acute myocardial infarction
ChiCTR2300074191Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in myocardial infarction (MI) (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoints: Lipid levels and Rate of lipoprotein(a) decline. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2300074191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074191.